Deals & Corporate Governance

  • May 27, 2025

    Paris VC Firm Cathay Closes $1B AI Venture Capital Fund

    Paris venture capital firm Cathay Innovation said Tuesday that it has closed a $1 billion fund focused on artificial intelligence investments.

  • May 27, 2025

    US Trustee Wants Steward Health Switched To Ch. 7

    The U.S. Trustee's Office is asking a Texas bankruptcy judge to convert Steward Health Care's Chapter 11 case to a court-supervised Chapter 7 liquidation, saying the hospital chain cannot pay the bills it has run up during its bankruptcy.

  • May 27, 2025

    Eli Lilly Inks $1B Deal For Non-Opioid Pain-Drug Maker

    Eli Lilly announced Tuesday that it has inked a potentially $1 billion deal to buy SiteOne Theraputics, giving the pharmaceutical giant access to a non-opiod pain medicine ready for phase 2 trials. 

  • May 23, 2025

    FTC Probing Alcon's $430M Lensar Deal

    The Federal Trade Commission has requested additional information about Swiss eye care company Alcon Inc.'s planned purchase of Florida-based medical technology developer Lensar Inc. in a deal worth up to $430 million.

  • May 23, 2025

    Biotech Insider Traded On $3.5B Novartis Deal, Feds Say

    A former board member at Chinook Therapeutics orchestrated an insider-trading scheme after learning about Novartis' plans to purchase the biotech company for $3.5 billion in 2023, according to an indictment announced Friday.

  • May 22, 2025

    EpiPen Direct Buyers, Mylan Get Final OK On Antitrust Deal

    Mylan Pharmaceuticals' $73.5 million settlement with a class of direct EpiPen buyers has received final approval from a Kansas federal judge, closing out claims from institutional drug resellers that Mylan worked with Pfizer to forestall an EpiPen generic from hitting the market and artificially inflating prices for the emergency injectable.

  • May 22, 2025

    Nostrum Cleared for $1.75M Sale Of Ohio Drug Facility

    Bankrupt drugmaker Nostrum Laboratories received approval from a New Jersey court for a $1.75 million sale of an Ohio facility after reaching an agreement with the buyer and lenders over the costs of removing controlled substances at the property.

  • May 21, 2025

    FTC Urges 8th Circ. Not To Pause In-House PBM Case

    The Eighth Circuit should once again say no to a request to pause the Federal Trade Commission's in-house case accusing three pharmacy benefit managers of hiking up the price of insulin to line their own pockets, the agency has told the appellate court.

  • May 21, 2025

    AbbVie Gets Victory In Allergan Shareholder Suit Upheld

    An Illinois state appellate panel said Wednesday that a trial court properly dismissed a shareholder class action against biopharmaceutical company AbbVie Inc. that accused the drugmaker of issuing unregistered shares to investors after acquiring Irish pharmaceutical company Allergan.

  • May 20, 2025

    Cancer Drug Co. Beats Investor Suit Over FDA Rejection

    Cancer drug company Checkpoint Therapeutics Inc. has permanently escaped a shareholder suit alleging it understated the likelihood the U.S. Food and Drug Administration would refuse approving Checkpoint's lead product candidate, with a New York federal judge ruling company statements were not shown to be false or made with scienter.

  • May 20, 2025

    Healthcare Deals This Week: 23andMe, Pfizer, Hengrui

    It was a busy few days for dealmaking in the healthcare sector, with major licensing transactions from names like Pfizer and Eli Lilly and a surprise buy of once-hot genetic testing company 23andMe from biotech Regeneron.

  • May 20, 2025

    Digital Health IPOs Serve As Litmus Test In Uncertain Markets

    While public markets have been turbulent in recent months, digital health companies appear to be bucking the trend, pushing to go public even as others wait on the sidelines.

  • May 20, 2025

    Nursing Homes Facing 'Corporate Death Penalty' Owe $15.4M

    The companies behind two Pittsburgh-area nursing homes convicted of falsifying staffing records were ordered Tuesday to pay a total of $15.35 million in restitution to the federal government, though the corporations' attorney told the judge that they had already received a "corporate death penalty" for their conviction.

  • May 19, 2025

    4th Circ. Partially Revives Eye Drop Maker's IP Theft Suit

    A Fourth Circuit panel partially revived Monday eye drop maker OSRX Inc.'s trade secret theft lawsuit against a former sales executive who is accused of defecting to rival ImprimisRx with OSRX's confidential information, affirming the lower court's decision to send claims against the ex-executive to arbitration, but rebooting allegations against ImprimisRx.

  • May 19, 2025

    Bluebird Beats Patent Case Over Blood Disease Therapies

    A Delaware federal judge has tossed a lawsuit against Bluebird Bio alleging two of its multimillion-dollar gene therapy treatments for blood disorders infringed patents held by San Rocco Therapeutics LLC, after the dispute had been narrowed by a previous claim construction ruling.

  • May 19, 2025

    NC Doctors Can't Block Pay Changes Amid Legal Challenge

    A group of anesthesiologists can't stop their governing board from imposing changes to their compensation while they sue for breach of contract, a state business court judge ruled Monday, finding the doctors have other ways of obtaining relief that negate the need for an injunction.

  • May 19, 2025

    Biotech Services Company Files Ch. 11 With $60M In Debt

    Contracted biotechnology research company AmplifyBio filed for Chapter 11 protection late Friday in Ohio bankruptcy court listing about $60 million in debt, saying it intends to sell its assets after failing to realize sufficient revenue to support its capital-intensive operations.

  • May 19, 2025

    BCLP Hires Career Crowell Commercial Atty In DC, Arizona

    Bryan Cave Leighton Paisner LLP has hired a former Crowell & Moring LLP commercial litigator who will split time between the firm's Phoenix and Washington, D.C., offices, and will bring his practice representing companies in high stakes healthcare and antitrust matters to the firm, according to a Monday announcement.

  • May 19, 2025

    Covington Corporate M&A Atty Moves To Clifford Chance

    Clifford Chance LLP has hired a Covington & Burling LLP partner for its U.S. corporate mergers and acquisitions practice to strengthen its capabilities in the healthcare and life sciences sector, the firm said Monday.

  • May 16, 2025

    Bank Balks At Nostrum Ch. 11 Sale Over Drug Disposal Issue

    Waterford Bank NA has objected to New Jersey drugmaker Nostrum Laboratories Inc.'s plan to sell an Ohio property, saying the bank doesn't want to be left to pay for the disposal of large quantities of controlled substances left at the site, an issue the parties are now negotiating ahead of a hearing next week.

  • May 15, 2025

    Ex-CEO Cops To Conspiracy Charge In $212M Fraud Case

    A New Jersey-based former CEO of a medical billing company has pled guilty to conspiring to commit securities fraud in connection with government claims he was part of a $212.5 million scheme to inflate the value of his company to defraud potential investors in a go-private transaction.

  • May 15, 2025

    NC Judge Warns Of Airing 'Dirty Laundry' In Doctors' Pay Clash

    A North Carolina business court judge on Thursday told a group of anesthesiologists and their business partners to seriously consider mediating a dispute over compensation, cautioning that if they choose to litigate, they should "be prepared for their dirty laundry to be aired for everyone to see."

  • May 14, 2025

    Integra Brass Face Investor Suit Over FDA Compliance Lapses

    Executives and directors of medical device company Integra Lifesciences Inc. were hit with a derivative suit alleging they misled investors about the company's compliance with regulatory standards for over five years, causing share declines when information regarding Integra's violations emerged.

  • May 14, 2025

    10th Circ. Chilly To Biotech's SEC Asset Freeze Challenge

    A panel of Tenth Circuit judges seemed skeptical Wednesday that a lower court had abused its discretion in granting a freeze of a biotech firm's assets in a suit brought by the U.S. Securities and Exchange Commission accusing the company and its founders of misappropriating roughly $9 million.

  • May 14, 2025

    Alnylam Halts Patent Row Over Pfizer, BioNTech COVID-19 Vax

    Alnylam Pharmaceuticals has decided to end a district court patent case over the COVID-19 vaccine made by Pfizer and BioNTech, asking a Delaware federal judge Tuesday to rule that the companies do not infringe its mRNA patents, while potentially setting the stage for an appeal.

Expert Analysis

  • An Overview Of 6 PBM Bills Moving Through Congress

    Author Photo

    As legislators turn to pharmacy benefit manager reform as a potential next step in addressing the cost of prescription drugs, six congressional committees have recently advanced PBM-related legislation with generally high bipartisan support, suggesting that a final package is likely to advance through Congress, say Rachel Stauffer and Katie Waldo at McDermott+Consulting.

  • What Large Language Models Mean For Document Review

    Author Photo

    Courts often subject parties using technology assisted review to greater scrutiny than parties conducting linear, manual document review, so parties using large language models for document review should expect even more attention, along with a corresponding need for quality control and validation, say attorneys at Sidley.

  • Participating In Living History Makes Me A Better Lawyer

    Author Photo

    My role as a baron in a living history group, and my work as volunteer corporate counsel for a book series fan association, has provided me several opportunities to practice in unexpected areas of law — opening doors to experiences that have nurtured invaluable personal and professional skills, says Matthew Parker at the Nebraska Department of Health and Human Services.

  • Private Equity Owners Can Remedy Law Firms' Agency Issues

    Author Photo

    Nonlawyer, private-equity ownership of law firms can benefit shareholders and others vulnerable to governance issues such as disparate interests, and can in turn help resolve agency problems, says Michael Di Gennaro at The Law Practice Exchange.

  • How To Protect Atty-Client Privilege While Using Generative AI

    Author Photo

    When using generative artificial intelligence tools, attorneys should consider several safeguards to avoid breaches or complications in attorney-client privilege, say Antonious Sadek and Christopher Campbell at DLA Piper.

  • How New Lawyers Can Leverage Feedback For Growth

    Author Photo

    Embracing constructive criticism as a tool for success can help new lawyers accelerate their professional growth and law firms build a culture of continuous improvement, says Katie Aldrich at Fringe Professional Development.

  • State Privacy Laws: Not As Comprehensive As You May Think

    Author Photo

    As more U.S. states enact privacy laws, companies must be aware that these laws vary in scope and content, meaning organizations should take a stringent approach to compliance by considering notice, choice and data security obligations, among other requirements, says Liisa Thomas at Sheppard Mullin.

  • ESG Around The World: Australia

    Author Photo

    Clive Cachia and Cathy Ma at K&L Gates detail ESG-reporting policies in Australia and explain how the country is starting to introduce mandatory requirements as ESG performance is increasingly seen as a key investment and corporate differentiator in the fight for global capital.

  • Address The Data Monopoly, Otherwise Tech Giants Control AI

    Author Photo

    It is likely that we will experience a severe monopoly on artificial intelligence systems and patents by the largest players in the tech industry, so the way we treat data needs to change, whether through the legislature, the courts or tech companies, says Pranav Katti at Barclay Damon.

  • Info Exchanges Must Stay Inside Now-Invisible Antitrust Lines

    Author Photo

    While the antitrust agencies recently withdrew long-standing enforcement policy statements for being "overly permissive" on information exchanges, we should not assume that all information exchanges are inherently suspect — they are still permissible if carefully constructed and vigorously managed, say attorneys at Nelson Mullins.

  • Twitter Legal Fees Suit Offers Crash Course In Billing Ethics

    Author Photo

    X Corp.'s suit alleging that Wachtell grossly inflated its fees in the final days of Elon Musk’s Twitter acquisition provides a case study in how firms should protect their reputations by hewing to ethical billing practices and the high standards for professional conduct that govern attorney-client relationships, says Lourdes Fuentes at Karta Legal.

  • Amgen-Horizon Deal May Signal FTC's Return To Bargaining

    Author Photo

    The Federal Trade Commission's recent settlement of its challenge to Amgen's proposed acquisition of Horizon Therapeutics marks the latest in a string of midlitigation settlements, and may signal that competition regulators are more inclined toward such negotiations following recent litigation losses, say attorneys at Freshfields.

  • ABA's Money-Laundering Resolution Is A Balancing Act

    Author Photo

    While the American Bar Association’s recently passed resolution recognizes a lawyer's duty to discontinue representation that could facilitate money laundering and other fraudulent activity, it preserves, at least for now, the delicate balance of judicial, state-based regulation of the legal profession and the sanctity of the attorney-client relationship, say attorneys at Ballard Spahr.